CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) have achieved full prospects in advanced non-small cell lung cancer (7) and melanoma (8), and ICIs have achieved excellent results in the treatment of various tumors, especially in patients with programmed cell death-ligand 1 (PD-L1) positive, microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR), or tumor mutational burden-high (TMB-H) (9–11).